NaviNet Prescription Authorization Submission An Overview



Agenda

- Introduction/Background
- NaviNet® Prescription Drug Authorization Submission
- Resources
 - Provider Resource Center
 - Pharmacy Policy Access
 - Medication Request Submission Form Access
- Questions



Introduction

What is NaviNet and why use it for Prescription Submission?


- It is a secure communication tool.
- It will minimize time spent using the phone and faxing authorizations.
- It will improve decision communication time to providers.

Why are we talking about it?

- Many are not aware of the ability to submit prescription authorizations on NaviNet.
- Many are not aware of how to submit prescription authorizations on NaviNet.
- Several factors with in the office setting disrupt the ongoing use of NaviNet for prescription authorizations.
 - Staff turnover, changing workflow, etc.



NaviNet Electronic Prescription Submission





Path of a Prior Authorization Submission



Physician staff enters prior authorization request:
NaviNet, Phone or FAX

Pharmacy care management representative accesses the request, prepares it for pharmacist review

Pharmacist reviews and decision is made

Approvals are then loaded into the system. RX can be filled for the member at the pharmacy






Denials go to a Highmark Medical Director (physician) for review and final decision



If denied, prescribing physician and member are notified in a timely manner


Confidential and Proprietary — not for distribution. © 2014 Highmark Inc. All rights reserved. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides a secure, web-based portal between providers and health care insurance companies.

NaviNet login page






Plan Central






Select a category. Choose Prescription Drug, select service provider






Form completion: Enter diagnosis and the drug requested.






The prescription drug search is a "contains within" search. ...






You can also access and search of the member's formulary...






Form Completion: Requested and alternative drugs tried info.






Form Completion: Comments: Medical Rationale/Treatment Plan.






The Response Form






The Response Form continued






NAVINET APPROVAL / DENIAL

- Decision will be communicated via the action item flag on the screen. Status update is faxed to provider office and letters are mailed to provider and member.
- Click the flag to learn the result of the request.
- If the authorization is accepted, the prescription may be processed
 - Allow time for the authorization to be processed by ESI/Medco
- If a denial is received, a new online form must be completed with information that may have been missing and resubmit. .





Resources





Provider Resource Center

The provider resource center is an online tool that can be used by the provider to access information specific to the following areas:


- Pharmacy Policy and Program Information
- The Electronic Formulary

The Provider Resource Center can be accessed in the following ways:

- NaviNet Plan Central > Resource Center (from the list of transactions on the left side of the screen)
- https://prc.highmark.com/rscprc/hbcbs/pub



Provider Resource Center NAVINET ACCESS























Access
Pharmacy Policies
through the Provider
Resource Center

Pharmacy Formulary Information >

Pharmacy Formulary Information >Is this a duplicate line

Highmark Pharmacy
Policies

Pharma

Category: Number: Subject: Effective Date B Effective Date E Original Date: Review Date(s):

Policy Applies t

Drugs Address

FDA Approved

Treatme

Treatme

systemi

Treatme

Treatme

Mechanism of A

Etanercept is a s

immunoglobulin

and lymphotoxir

C(H)2 and C(H)3

metalloproteina

Limitations of C

 Etanercept should not be used in conjunction with Raptiva, Remicade, Amevive, Humira, or Kineret.

Approval Criteria: When a benefit, etanercept may be approved when all of the following criteria are met:

- Etanercept is to be used for the reduction in the signs and symptoms of moderately to severely active rheumatoid arthritis(ICD9 714.0) OR
- Etanercept is to be used for reducing the signs and symptoms of moderately to severely active polyarticular-course juvenile idiopathic arthritis (ICD 9 714.3x) in patients 2 years of age and older who have had an inadequate response to one or more DMARBo SP.
- Etanercept is to be used for reducing the signs and symptoms of active arthritis in patients with psoriatic arthritis (ICD9 696.0) OR
- Etanercept is to be used for reducing the signs and symptoms in patients with ankylosing spondylitis (ICD9 720.0) OR
- Etanercept is to be used for the treatment of moderate to severe psoriasis(ICD9 696.1) in patients
 who have had an inadequate response to systemic (e.g. methotrexate, cyclosporine) therapy OR
 phototherapy (e.g. PLVA, UVB)

Use of etanercept for disease states outside of its FDA-approved indications should be denied based on the lack of clinical data to support its effectiveness and safety in other conditions.

Duration of Authorization:

If approved, up to a lifetime authorization may be granted

References:

- Leonardi CL, Powers JL, Matheson RT, et. al. Etanercept as Monotherapy in Patients with Psoriasis. N Engl J Med. 2003;349:2014-2022.
- 2. Enbrel (etanercept). Prescribing information. Thousand Oaks, CA: Immunex Corporation, 2004: April.
- Bathon JM, Martin RW, Fleischmann RM, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-1593.
- Goldenberg MM: Etanercept, a noval drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999; 21(1):75-87.
- Gorman JD, Sack KE, & Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346(18):1349-1356.
 Iver S, Yamayuchi P. & Love N. I.: Flanerport for severe psoriasis and psoriatic arthritis:
- Iyer S, Yamauchi P, & Lowe NJ: Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Brit J Dermatol 2002; 146:118-121.
 Johnsen AK, Schiff MH, Mease PJ, et al: Comparison of 2 doses of etanercept (50 vs 100 mg) in
- Johnsen AK, Sohrt MH, Mease PJ, et al: Companson of 2 doses of etanercept (5U vs 10U mg) active rheunatoid arthritis: a randomized double blind study. J Rheumatol 2006; 33(4):659-684
 Kietz DA, Pepmueller PH, & Moore TL: Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002; 61:171-1715.
- Newn HJ, Cote TR, Cuffe MS, et al: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138:807-811.
- Leombruno JP, Einarson TR, & Keystone EC: The safety of anti-Tumor Necrosis Factor treatments in rheumatolic arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2008
- Leonardi CL, Powers JL, Matheson RT, et al: Etanercept as monotherapy in patients with posoriasis. N Engl J Med 2003; 349(21):2014-2022.
- Lovell DJ, Giannini EH, Reiff A, et al: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342(11):763-769.
- Mease PJ, Goffe BS, Metz J, et al: Etanercept in the treatment of psoriatic arthritis and psoriasis a randomised, trial. Lancet 2000; 356:385-390.

4:657-663. pt in treatment of

of Etanercept ing spondylitis. Ann

dified: September


006. Last Modified:

bing or the practice of nay vary for individual

nes are the proprietary vever, limited copying of



Provider Resource Center PRESCRIPTION DRUG MEDICATION REQUEST FORM





Questions and Answers

Please Contact your Provider Relations Representative with any questions or concerns you may still have following the webinar.

The Webinar training material has been sent to each registered participant. This information is also available on the Provider Resource Center (PRC) in NaviNet Plan Central by accessing the Pharmacy/Formulary Information site or the On-line Provider Training Link, Pharmacy Authorization Submission Process.

FAQ's are being created following each session. The document will also be posted On-Line with the Presentation



